Section Arrow
CTNM.NASDAQ
- Contineum Therapeutics
Quotes are at least 15-min delayed:2026/09/05 02:44 EDT
Regular Hours
Last
 16.7
-0.87 (-4.95%)
Day High 
17.71 
Prev. Close
17.57 
1-M High
17.785 
Volume 
346.23K 
Bid
16.68
Ask
24
Day Low
16.495 
Open
17.38 
1-M Low
14.1 
Market Cap 
661.00M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 16.98 
20-SMA 15.98 
50-SMA 15.28 
52-W High 17.785 
52-W Low 8.6 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.72/-1.70
Enterprise Value
666.91M
Balance Sheet
Book Value Per Share
6.37
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
IMRNImmuron Limited1.8+0.69+62.16%-- 
RXRXRecursion Pharmaceuticals3.63+0.19+5.52%-- 
CMNDClearmind Medicine Inc.1.16-0.54-31.76%-- 
MRNAModerna145.55-3.32-2.23%-- 
RAREUltragenyx Pharmaceutical15.3+0.45+3.03%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.